Related Experiment Video
Updated: Oct 11, 2025
Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer
Published on: October 4, 2022
[Serum of Mice Immunized with Mt1-MMP Metalloproteinase Reduces Migration Potential of Pancreatic Cancer Cells]
N A Mitkin1,2, A S Ustiugova1, A N Uvarova1
1Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991 Russia.
Abstract:
Expression levels of matrix metalloproteinases, in particular MT1-MMP, are elevated in pancreatic cancer (PC) cells, and this is associated with increased tumor proliferation, invasion, and migration. MT1-MMP is considered a promising target for drug therapy of PC, but the use of inhibitors and therapeutic antibodies to MT1-MMP is limited because maximal efficiency is only observed in a narrow time interval, at the early asymptomatic stages of the disease. This problem could be solved by immunization to MPs at the moment of detection of the primary tumor. This therapeutic effect could be provided by specific antibodies that can be re-produced in case of relapses. Here, we selected the optimal mode for immunization of mice with MT1-MMP fragments that allows us to obtain a high titer of specific antibodies in the blood serum. The obtained antiserums effectively inhibited MT1-MMP enzymatic activity, migration of PANC-02 PC cells through the collagen matrix, and activation of the main inducers of epithelial -mesenchymal transition, TGF-β and MMP-2. These results maybe useful in the development of drugs for PC treatment, and the approach we propose might form the basis for design of antitumor drugs with prolonged action.
Insights
Researchers developed an immunization strategy using MT1-MMP fragments to generate specific antibodies. These antibodies effectively inhibited pancreatic cancer cell invasion and key molecular pathways, offering a potential new therapeutic approach for pancreatic cancer.
Area of Science:
- Oncology
- Biochemistry
- Immunology
Background:
- Elevated matrix metalloproteinase MT1-MMP expression in pancreatic cancer (PC) correlates with increased tumor progression.
- Current MT1-MMP inhibitors and antibodies show limited efficacy due to a narrow therapeutic window at early disease stages.
- Immunization against MT1-MMP at primary tumor detection could overcome these limitations, providing sustained antibody production.
Purpose of the Study:
- To establish an optimal immunization protocol in mice using MT1-MMP fragments.
- To generate high-titer specific antibodies against MT1-MMP.
- To evaluate the therapeutic potential of these antibodies in preclinical models of pancreatic cancer.
Main Methods:
- Selected optimal immunization modes using MT1-MMP fragments in mice.
- Assessed antibody titers in blood serum.
- Tested the efficacy of generated antiserums against MT1-MMP enzymatic activity, PANC-02 cell migration through collagen, and TGF-β/MMP-2 activation.
Main Results:
- Successfully obtained high titers of specific antibodies against MT1-MMP fragments.
- The generated antiserums demonstrated significant inhibition of MT1-MMP enzymatic activity.
- Antiserums effectively reduced PANC-02 cell migration and suppressed the activation of TGF-β and MMP-2, key inducers of epithelial-mesenchymal transition.
Conclusions:
- The proposed immunization strategy effectively generates functional antibodies against MT1-MMP.
- These antibodies show promise in inhibiting key aspects of pancreatic cancer progression.
- This approach may lead to the development of novel, long-acting therapeutic drugs for pancreatic cancer treatment.
